Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2023-05-03 Audit Report / Informat…
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Sprawozdanie Finansowe Bioceltix S.A. za okres 01.01.2022-31.12.2022 r.
Audit Report / Information Classification · 1% confidence The document text explicitly states multiple times that it is a "Sprawozdanie finansowe za okres 01.01.2022 r. – 31.12.2022 r." which translates to 'Financial statement for the period 01.01.2022 – 31.12.2022'. It contains a detailed Table of Contents listing standard financial statements (Balance Sheet, Income Statement, Cash Flow Statement) and explanatory notes. The period covered is a full fiscal year (January 1st to December 31st). This content strongly indicates a comprehensive annual financial report prepared according to local accounting standards (Polish GAAP, as indicated by 'polskimi zasadami rachunkowości'). Although the document is Polish, the closest equivalent category for a full annual financial report is '10-K' (Annual Report), as it covers the entire fiscal year and contains the full set of financial statements, distinguishing it from an 'IR' (Interim Report) or 'ER' (Earnings Release). Given the comprehensive nature and full-year coverage, '10-K' is the most appropriate classification, even if the specific regulatory filing form name differs from the US SEC standard. FY 2022
2023-05-03 Polish
Tekst jednolity Statutu Spółki
Governance Information Classification · 1% confidence The document text consists of sections titled "STATUT SPÓŁKI BIOCELTIX SPÓŁKA AKCYJNA" (Statute of Bioceltix Joint Stock Company) and details regarding its formation, company name, registered office, scope of activity, duration, subject of activity (including PKD codes), and capital structure (share capital, types of shares, conversion rules). This content is characteristic of a company's foundational legal document, which in the context of corporate filings, aligns best with Governance Information or a foundational document that dictates corporate structure. Since 'Governance Information (Code: CGR)' covers internal rules and board structure, and this document explicitly details the Statute (which defines these rules), CGR is the most appropriate classification. It is not a financial report (10-K, IR), an announcement (RPA, ER), or a specific transaction report (DIV, POS).
2023-04-28 Polish
Rejestracja podwyższenia kapitału zakładowego i zmian w statucie Spółki - Content (PL)
AGM Information Classification · 1% confidence The document text is a formal announcement from the Management Board ('Zarząd') of Bioceltix S.A. It explicitly states that the company's share capital ('kapitał zakładowy') was increased due to the issuance of Series K shares and details the resulting changes to the company's articles of association ('statut'). The core subject is the formal registration of a capital increase and subsequent amendment of the charter, which directly relates to the company's capital structure and financing activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions attaching the consolidated articles of association, the primary purpose is reporting the capital change event itself, not just announcing the publication of a report.
2023-04-28 Polish
Zawiadomienie z dnia 4 kwietnia 2023 roku przekazane przez Infini ASI sp. z o.o.
Major Shareholding Notification Classification · 1% confidence The document is a formal notification ('ZAWIADOMIENIE') addressed to the Polish Financial Supervision Authority ('Komisja Nadzoru Finansowego' - KNF) regarding a change in shareholding percentage. It explicitly cites Article 69 of the Polish Act on Public Offering ('Ustawa o ofercie publicznej...'), which governs mandatory notifications when ownership crosses certain thresholds (like 5%, 10%, 33%, etc.). The text details the transaction (sale of 150,000 shares) and the resulting change in ownership percentage from 13.97% to 9.78%, falling below the 10% threshold. This type of mandatory disclosure concerning changes in significant share ownership aligns perfectly with the definition of Major Shareholding Notification (MRQ).
2023-04-05 Polish
Zawiadomienie o zmianie udziału w ogólnej liczbie głosów na Walnym Zgromadzeniu Emitenta - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement (672 characters) from the Management Board of Bioceltix S.A. It explicitly states that a notification regarding a decrease in the total number of votes at the General Meeting, submitted by Infini Alternatywna Spółka Inwestycyjna sp. z o.o., was received today (April 4, 2023). The text concludes with: 'Treść otrzymanego zawiadomienia stanowi załącznik do niniejszego raportu' (The content of the received notification constitutes an attachment to this report). This structure—a brief announcement stating that a specific notification (related to voting rights/shareholding changes) is attached—strongly suggests this is an announcement about the publication of the underlying document, rather than the full report itself. The subject matter concerns voting rights/shareholding changes, which aligns closely with Major Shareholding Notification (MRQ) or potentially Declaration of Voting Results (DVA), but given the context of receiving a formal notification about voting rights changes, MRQ (Major Shareholding Notification) is the most appropriate fit for reporting changes in ownership that affect voting power, even if the underlying document is a specific regulatory filing under Polish law (Art. 69). However, since the document is merely announcing the receipt of a notification about a change in voting rights/shareholding, and the text is very short, it fits the 'MENU VS MEAL' rule for an announcement. If the content was the full notification, MRQ would apply. As it is an announcement of a notification, RPA (Report Publication Announcement) is a strong candidate, but MRQ specifically covers changes in significant share ownership. Given the content is about a change in the 'total number of votes at the General Meeting' (zmniejszeniu udziału w ogólnej liczbie głosów na Walnym Zgromadzeniu Spółki), this is fundamentally a change in significant shareholding/voting power. I will classify it as MRQ, as it is the specific subject matter, but acknowledge the RPA possibility due to length. Since MRQ is a specific filing type for shareholding changes, I prioritize the subject matter over the announcement format, as MRQ filings often contain the attached notification itself. If the document was purely about the *timing* of a report release, RPA would be better. Here, the core information (the change in voting rights) is being disclosed via the attached document. I will stick with MRQ as the most specific content classification.
2023-04-05 Polish
Powiadomienie o transakcjach, o których mowa w art. 19 ust. 1 rozporządzenia MAR
Director's Dealing Classification · 1% confidence The document is titled "Powiadomienie o transakcjach, o których mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transactions referred to in Article 19(1) of the MAR Regulation). This regulation (Market Abuse Regulation) mandates reporting of transactions conducted by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. The content details the name of the associated person, their position, the issuer (Bioceltix S.A.), the instrument (shares), the transaction type ('Zbycie' - Disposal), price, and volume. This structure perfectly matches the definition of Director's Dealing (insider trades) reports, which are specifically covered by the DIRS code in our schema.
2023-04-03 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.